Activity of TGR-1202, a novel once-daily PI3Kδ inhibitor, in patients with relapsed or refractory hematologic malignancies.
Howard A. Burris
Research Funding - TG Therapeutics
Manish R. Patel
Research Funding - TG Therapeutics
Mark C. Lanasa
Research Funding - TG Therapeutics
Danielle Brander
Research Funding - TG Therapeutics
Owen A. O'Connor
Research Funding - TG Therapeutics
Changchun Deng
Research Funding - TG Therapeutics
Martin Gutierrez
Research Funding - TG Therapeutics
Suzanne Fields Jones
No relevant relationships to disclose
John G. Kuhn
Consultant or Advisory Role - TG Therapeutics
Hari P. Miskin
Employment or Leadership Position - TG Therapeutics
Stock Ownership - TG Therapeutics
Peter Sportelli
Employment or Leadership Position - TG Therapeutics
Stock Ownership - TG Therapeutics
Swaroop Vakkalanka
Employment or Leadership Position - Rhizen Pharmaceuticals
Stock Ownership - Rhizen Pharmaceuticals
Ian Flinn
Research Funding - TG Therapeutics